{
    "nct_id": "NCT04746924",
    "official_title": "A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer",
    "inclusion_criteria": "1. Histologically or cytologically documented locally advanced or recurrent non-small cell lung cancer (NSCLC) that is not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic-nonsquamous or squamous NSCLC.\n2. No prior systemic treatment for metastatic NSCLC.\n3. Agreement to provide archival tissue or fresh biopsy (if archival tissue is not available).\n4. Tumors with PD-L1 expressed in ≥ 50% tumor cells.\n5. At least 1 measurable lesion as defined per RECIST v1.1.\n6. ECOG Performance Status ≤ 1.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Known mutations in the epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, or ROS1.\n2. Prior therapy with an anti-programmed cell death protein (anti-PD)-1, anti-PD-ligand (L)-1, anti-PD-ligand-2, anti-T-cell immunoglobulin and ITIM (anti-TIGIT) domain, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.\n3. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.\n4. Active autoimmune diseases or history of autoimmune diseases that may relapse.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply",
    "miscellaneous_criteria": "Key"
}